Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Fuji
Cerilliant
Healthtrust
Novartis
Merck
QuintilesIMS
Julphar
Johnson and Johnson
McKesson

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,248,123

« Back to Dashboard

Which drugs does patent 9,248,123 protect, and when does it expire?

Patent 9,248,123 protects CONTRAVE and is included in one NDA.

This patent has seventeen patent family members in eleven countries.
Summary for Patent: 9,248,123
Title:Methods of providing weight loss therapy in patients with major depression
Abstract: Disclosed are methods of providing weight loss therapy, particularly for patients suffering from major depression.
Inventor(s): Dunayevich; Eduardo (San Diego, CA), Tollefson; Gary (Indianapolis, IN)
Assignee: Orexigen Therapeutics, Inc. (La Jolla, CA)
Application Number:12/987,909
Patent Claim Types:
see list of patent claims
Use; Dosage form; Composition; Formulation;

Drugs Protected by US Patent 9,248,123

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Orexigen CONTRAVE bupropion hydrochloride; naltrexone hydrochloride TABLET, EXTENDED RELEASE;ORAL 200063-001 Sep 10, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up USE OF NALTREXONE AND BUPROPION FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,248,123

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2011203867 ➤ Sign Up
Australia 2016201325 ➤ Sign Up
Brazil 112012016783 ➤ Sign Up
Canada 2785822 ➤ Sign Up
China 102724878 ➤ Sign Up
European Patent Office 2523557 ➤ Sign Up
Israel 220610 ➤ Sign Up
Japan 2013516493 ➤ Sign Up
Japan 2016138142 ➤ Sign Up
Japan 6196041 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Teva
Cerilliant
Federal Trade Commission
Farmers Insurance
UBS
Boehringer Ingelheim
Queensland Health
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot